Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Advancing Safe Medications for Moms and Babies Act of 2023
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Advancing Safe Medications for Moms and Babies Act of 2023
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2026 · third_quarter · Q3
inclusion of pregnant and lactating women in clinical trials, federal support for maternal mortality review committees and perinatal quality collaboratives
FY 2027 funding for the National Institutes of Health, the Centers for Disease Control and Prevention, the Agency for Healthcare Research & Quality, and the Health Resources and Services Administration
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Source: Senate LDA
Advancing Safe Medications for Moms and Babies Act of 2023
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Advancing Safe Medications for Moms and Babies Act of 2023
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Advancing Safe Medications for Moms and Babies Act of 2023
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Advancing Safe Medications for Moms and Babies Act of 2023
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Advancing Safe Medications for Moms and Babies Act of 2023
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Advancing Safe Medications for Moms and Babies Act of 2023
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117) and reintroduction of the Black Maternal Health Momnibus. Urging FDA to take actions to ensure continued access to mifepristone.
Women's Health Protection Act of 2021
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Women's Health Protection Act (H.R.3755/S.4132)
Honoring Family-Friendly Workplaces Act
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Maternal Health Quality Improvement Act (S. 1675/HR 4837)
Advancing Safe Medications for Moms and Babies Act of 2022
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for Black Maternal Momnibus (HR 959/S 346); Advancing Safe Medications for Moms and Babies Act (HR 9487)
Black Maternal Health Momnibus Act of 2021
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for Black Maternal Momnibus (HR 959/S 346); Advancing Safe Medications for Moms and Babies Act (HR 9487)
Black Maternal Health Momnibus Act of 2021
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for Black Maternal Momnibus (HR 959/S 346) programs
Black Maternal Health Momnibus Act of 2021
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Maternal Health Quality Improvement Act (S. 1675/HR 4837)
Black Maternal Health Momnibus Act of 2021
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Women's Health Protection Act (H.R.3755/S.4132)
Maternal Health Quality Improvement Act
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Maternal Health Quality Improvement Act (S. 1675/HR 4837)
Black Maternal Health Momnibus Act of 2021
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Maternal Health Quality Improvement Act (S. 1675/HR 4837)
Black Maternal Health Momnibus Act of 2021
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Women's Health Protection Act (H.R.3755/S.4132)
Black Maternal Health Momnibus Act of 2021
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for Black Maternal Momnibus (HR 959/S 346) programs
Black Maternal Health Momnibus Act of 2021
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for Black Maternal Momnibus (HR 959/S 346); Advancing Safe Medications for Moms and Babies Act (HR 9487)
Women’s Health Protection Act of 2022
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Women's Health Protection Act (H.R.3755/S.4132)
Honoring Family-Friendly Workplaces Act
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials, including COVID-19 vaccine trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Maternal Health Quality Improvement Act (S. 1675/HR 4837)
Black Maternal Health Momnibus Act of 2021
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials, including COVID-19 vaccine trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/s 346) programs
Black Maternal Health Momnibus Act of 2021
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials, including COVID-19 vaccine trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Maternal Health Quality Improvement Act (S. 1675/HR 4837)
Maternal Health Quality Improvement Act
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials, including COVID-19 vaccine trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Maternal Health Quality Improvement Act (S. 1675/HR 4837)
Black Maternal Health Momnibus Act of 2021
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials, including COVID-19 vaccine trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Maternal Health Quality Improvement Act (S. 1675/HR 4837)
Black Maternal Health Momnibus Act of 2021
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials, including COVID-19 vaccine trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/s 346) programs
Maternal Health Quality Improvement Act of 2020
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
Maternal Health Quality Improvement Act of 2020
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
Maternal Health Quality Improvement Act of 2020
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995)
Helping Medicaid Offer Maternity Services Act of 2020
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995)
Helping Medicaid Offer Maternity Services Act of 2020
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
Helping Medicaid Offer Maternity Services Act of 2020
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
Black Maternal Health Momnibus Act of 2020
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995)
Black Maternal Health Momnibus Act of 2020
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
Black Maternal Health Momnibus Act of 2020
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
Maternal Health Pandemic Response Act of 2020
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
Maternal Health Pandemic Response Act of 2020
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
Black Maternal Health Momnibus Act of 2020
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
Black Maternal Health Momnibus Act of 2020
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
Black Maternal Health Momnibus Act of 2020
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995)
Mothers and Newborns Success Act
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
Mothers and Newborns Success Act
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
Maternal Health Pandemic Response Act of 2020
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
Maternal Health Pandemic Response Act of 2020
Client: SOCIETY FOR MATERNAL-FETAL MEDICINE · Firm: SOCIETY FOR MATERNAL-FETAL MEDICINE
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2026 · second_quarter · Q2
inclusion of pregnant and lactating women in clinical trials, federal support for maternal mortality review committees and perinatal quality collaboratives
FY 2027 funding for the National Institutes of Health, the Centers for Disease Control and Prevention, the Agency for Healthcare Research & Quality, and the Health Resources and Services Administration
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2026 · first_quarter · Q1
FY 2026 and FY 2027 funding for the National Institutes of Health, the Centers for Disease Control and Prevention, the Agency for Healthcare Research & Quality, and the Health Resources and Services Administration
inclusion of pregnant and lactating women in clinical trials, federal support for maternal mortality review committees and perinatal quality collaboratives
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2025 · fourth_quarter · Q4
FY 2025 and FY 2026 funding for the National Institutes of Health, the Centers for Disease Control and Prevention, the Agency for Healthcare Research & Quality, and the Health Resources and Services Administration
inclusion of pregnant and lactating women in clinical trials, federal support for maternal mortality review committees and perinatal quality collaboratives
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2025 · third_quarter · Q3
inclusion of pregnant and lactating women in clinical trials, federal support for maternal mortality review committees and perinatal quality collaboratives
FY 2025 and FY 2026 funding for the National Institutes of Health, the Centers for Disease Control and Prevention, the Agency for Healthcare Research & Quality, and the Health Resources and Services Administration
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2025 · second_quarter · Q2
FY 2025 and FY 2026 funding for the National Institutes of Health, the Centers for Disease Control and Prevention, the Agency for Healthcare Research & Quality, and the Health Resources and Services Administration
inclusion of pregnant and lactating women in clinical trials, federal support for maternal mortality review committees and perinatal quality collaboratives
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2025 · first_quarter · Q1
FY 2025 and FY 2026 funding for the National Institutes of Health, the Centers for Disease Control and Prevention, the Agency for Healthcare Research & Quality, and the Health Resources and Services Administration
inclusion of pregnant and lactating women in clinical trials, federal support for maternal mortality review committees
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2024 · fourth_quarter · Q4
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Increases in funding in FY 2025 for maternal and infant health programs at NIH, HRSA, AHRQ, FDA, and CDC.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2024 · third_quarter · Q3
Increases in funding in FY 2024 and FY 2025 for maternal and infant health programs at NIH, HRSA, AHRQ, FDA, and CDC.
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2024 · second_quarter · Q2
Increases in funding in FY 2024 and FY 2025 for maternal and infant health programs at NIH, HRSA, AHRQ, FDA, and CDC.
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2024 · first_quarter · Q1
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Increases in funding in FY 2024 and FY 2025 for maternal and infant health programs at NIH, HRSA, AHRQ, FDA, and CDC.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2023 · fourth_quarter · Q4
Increases in funding in FY 2024 for maternal and infant health programs at NIH, HRSA, AHRQ, FDA, and CDC.
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2023 · third_quarter · Q3
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Increases in funding in FY 2024 for maternal and infant health programs at NIH, HRSA, AHRQ, FDA, and CDC.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2023 · second_quarter · Q2
Increases in funding in FY 2024 for maternal and infant health programs at NIH, HRSA, AHRQ, FDA, and CDC.
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117)
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2023 · first_quarter · Q1
Increases for funding in FY 2024 for maternal and infant health programs at NIH, HRSA, AHRQ, FDA, and CDC. Increases for funding for reproductive health programs at HRSA, USAID
maternal health legislation, including the Advancing Safe Medications for Moms and Babies Act (HR 1117) and reintroduction of the Black Maternal Health Momnibus. Urging FDA to take actions to ensure continued access to mifepristone.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2022 · fourth_quarter · Q4
Funding for maternal health programs at CDC, NIH, HRSA, AHRQ in FY2022/FY2023; inclusion of pregnant and lactating people in clinical trials and research
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for Black Maternal Momnibus (HR 959/S 346); Advancing Safe Medications for Moms and Babies Act (HR 9487)
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2022 · third_quarter · Q3
Funding for maternal health programs at CDC, NIH, HRSA, AHRQ in FY2022/FY2023; inclusion of pregnant and lactating people in clinical trials and research
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for Black Maternal Momnibus (HR 959/S 346) programs
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2022 · second_quarter · Q2
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Women's Health Protection Act (H.R.3755/S.4132)
Funding for maternal health programs at CDC, NIH, HRSA, AHRQ in FY2022/FY2023; inclusion of pregnant and lactating people in clinical trials and research
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2022 · first_quarter · Q1
Funding for maternal health programs at CDC, NIH, HRSA, AHRQ in FY2022/FY2023; inclusion of pregnant and lactating people in clinical trials and research
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Maternal Health Quality Improvement Act (S. 1675/HR 4837)
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2021 · fourth_quarter · Q4
FY 2022 funding for maternal health programs at CDC, NIH, HRSA, AHRQ; inclusion of pregnant and lactating people in clinical trials and research
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials, including COVID-19 vaccine trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/S 346) programs; support for the Maternal Health Quality Improvement Act (S. 1675/HR 4837)
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2021 · third_quarter · Q3
FY 2022 funding for maternal health programs at CDC, NIH, HRSA, AHRQ; inclusion of pregnant and lactating people in clinical trials and research
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials, including COVID-19 vaccine trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people; support for Black Maternal Momnibus (HR 959/s 346) programs
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2021 · second_quarter · Q2
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials, including COVID-19 vaccine trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people
FY 2022 funding for maternal health programs at CDC, NIH, HRSA, AHRQ; inclusion of pregnant and lactating people in clinical trials and research
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2021 · first_quarter · Q1
FY 2022 funding for maternal health programs at CDC, NIH, HRSA, AHRQ; inclusion of pregnant and lactating people in clinical trials and research
legislation to extend postpartum Medicaid coverage to 12 months; inclusion of pregnant and lactating people in clinical trials, including COVID-19 vaccine trials; support for public health surveillance infrastructure to track the impact of COVID-19 on pregnant and lactating people
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2020 · fourth_quarter · Q4
FY21 Labor-Health and Human Services-Education appropriations/maternal and infant health/AHRQ/NIH/CDC/HRSA; COVID-19 supplemental appropriations - AHRQ/NIH/CDC/HRSA
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2020 · third_quarter · Q3
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995); Mothers and Newborns Success Act (S 4269), Maternal Health Pandemic Response Act of 2020 (HR 8027/S 4769)
FY21 Labor-Health and Human Services-Education appropriations/maternal and infant health/AHRQ/NIH/CDC/HRSA; COVID-19 supplemental appropriations - AHRQ/NIH/CDC/HRSA
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2020 · second_quarter · Q2
FY21 Labor-Health and Human Services-Education appropriations/maternal and infant health/AHRQ/NIH/CDC/HRSA; COVID-19 supplemental appropriations - AHRQ/NIH/CDC/HRSA
Black Maternal Health Momnibus (HR 6142/S 3424); maternal mortality, severe maternal morbidity, research in pregnancy; COVID-19 issues: PPE and testing in maternity care units, incorporating pregnant women in clinical trials for COVID treatments and therapeutics; Helping MOMS Act (HR 4996), Maternal Health Quality Improvement Act of 2019 (HR 4995)
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
SOCIETY FOR MATERNAL-FETAL MEDICINE via SOCIETY FOR MATERNAL-FETAL MEDICINE
2020 · second_quarter · RA
FY21 Labor-Health and Human Services-Education appropriations/maternal and infant health/AHRQ/NIH/CDC/HRSA maternity care, research & pregnancy, maternal mental health
FY21 Labor-Health and Human Services-Education appropriations/maternal and infant health/AHRQ/NIH/CDC/HRSA maternity care, research & pregnancy, maternal mental health